October 3, 2025
1 min read

Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate

The initial part of the up-to-$339 million funding will largely be used to establish U.S. manufacturing for the non-vaccine flu preventive candidate, with additional options tied to further clinical studies, Cidara said.

Leave a Reply

Your email address will not be published.

Previous Story

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Next Story

FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing

Previous Story

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Next Story

FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing

Latest from Blog

NEWS CENTER Maine

Through in-depth storytelling, through direct contact on digital on social platforms, through long-standing community service programs like Coats & Toys for Kids, Project Heat and Buddy to Buddy, NEWS CENTER Maine is
Go toTop